Pharmacor

2010

Breast Cancer (Event Driven)

Report Authors
Niamh Murphy, Ph.D.
Alison Mathewson, M.Sc., Ph.D.
Regina E. Jammen, M.S.
  • Pages:286
  • Tables:49
  • Figures:17
  • Citations:355
  • Drugs:44
  • Interviews:33

Introduction:

Last Updated 20 April 2010
Despite earlier diagnosis and improved treatment, the high incidence of breast cancer (CaB) makes it the second-leading cause of cancer-related deaths in women. In 2008, more than 450,000 incident cases were diagnosed in the major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan)—incident cases that may be divided among numerous subpopulations, each with distinctly different disease characteristics. Hormonal, chemotherapeutic, and targeted therapies aim to address the needs of these specific patient segments, but current drugs have very little impact on improving the prognosis of patients with metastatic or triple-negative CaB. The unmet need in these patient segments reflects a considerable opportunity for drug developers, particularly for those seeking to advance targeted therapies. Targeted therapies have the greatest commercial potential in the CaB market as a result of their premium pricing and limited generic erosion during our forecast period. The CaB therapy market will continue to grow owing to the uptake of premium-priced treatments, launches of emerging therapies, and a growing incident population.

Questions Answered in This Report:

  *   PARP inhibitors are among the numerous emerging therapies being explored for BRCA1/BRCA2-mutated, basal-like, or triple-negative CaB—patient populations who have traditionally been underserved because of the lack of effective therapies. What do PARP inhibitors offer in terms of efficacy and safety? How do key opinion leaders perceive these drugs? What is the commercial potential of the PARP inhibitors in the CaB market?

  *   Bevacizumab entered the CaB market as the first anti-vascular endothelial growth factor (VEGF) therapy for the treatment of metastatic CaB. Numerous other angiogenesis inhibitors are in development for CaB, of which ramucirumab is among the most promising. What do experts think about the potential of this drug class? How will a new VEGF inhibitor be used? Will any VEGF inhibitors be approved for the treatment of CaB patients in the adjuvant setting? How will bevacizumab’s sales be affected by the launch of new VEGF inhibitors?

  *   Pan-kinase inhibitors will likely play a role in the treatment of CaB by 2018. As developers seek CaB drugs with improved efficacy, they are also interested in drugs capable of evading cancer cells’ drug resistance mechanisms. How will a pan-kinase inhibitor be prescribed? What are the potential advantages and disadvantages of such a drug? What do experts think about the pan-kinase inhibitors in clinical development?

  *   Trastuzumab (Roche/Chugai’s Herceptin) offers CaB patients who are positive for the human epidermal growth factor receptor  (HER2) an effective and well-tolerated treatment in both the adjuvant and metastatic settings. How will physicians treat patients who experience progressed disease but were already treated with trastuzumab? What will the role of combination targeted therapies be during the 2008-2018 study period? How will trastuzumab fare against current and emerging treatments for HER2-positive patients? How will the possible launch of a trastuzumab biosimilar affect the HER2-positive market?

  *   In May 2008, the FDA approved the TCH regimen—docetaxel (Sanofi-Aventis’s Taxotere), carboplatin (Bristol-Myers Squibb’s Paraplatin, generics), and trastuzumab—for the adjuvant treatment of HER2-positive CaB; in July 2008, however, Europe’s Committee for Medicinal Products for Human Use (CHMP) rejected the TCH regimen. How has the regimen been received in the United States? What do European oncologists think about such a combination for CaB?

  *   To date, no therapeutic vaccines have been launched in any of the major oncology markets, but several drug developers are seeking to harness the commercial potential of an effective CaB vaccine. Two therapies in Phase III development—Apthera’s NeuVax and Merck KGaA/Oncothyreon’s Stimuvax—hold the potential for becoming among the first vaccines to enter this market. What do thought-leading oncologists think of vaccines’ potential in the CaB market? Will any vaccines launch for CaB during the 2008-2018 study period?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 33 country-specific interviews with CaB thought leaders.

Epidemiology: Incidence and prevalence of stages I, IIa, IIb, III, and IV CaB; incidence of hormonal CaB by stage at diagnosis; prevalence of hormonal CaB at diagnosis; incidence of nonhormonal CaB by stage at diagnosis; prevalence of nonhormonal CaB at diagnosis; incidence of HER2-positive CaB by stage at diagnosis; prevalence of HER2-positive CaB at diagnosis; incidence of basal-like CaB by stage at diagnosis; prevalence of basal-like CaB at diagnosis; incidence of premenopausal CaB by stage at diagnosis; incidence of postmenopausal CaB by stage at diagnosis.

Population segments in market forecast: Adjuvant and neoadjuvant HR+/HER2- premenopausal, adjuvant and neoadjuvant HR+/HER2+ postmenopausal, adjuvant and neoadjuvant HR+/HER2+ premenopausal, adjuvant and neoadjuvant HR-/HER2+, adjuvant and neoadjuvant HR-/HER2- (triple-negative), first-line metastatic HR+/HER2-, second-line metastatic HR+/HER2-, third/fourth-line metastatic HR+/HER2-, first-line metastatic HER2+ (HR+ and HR-), second-line metastatic HER2+ (HR+ and HR-), third/fourth-line metastatic HER2+ (HR+ and HR-), first-line metastatic HR-/HER2- (triple-negative), second-line metastatic HR-/HER2- (triple-negative), third/fourth metastatic line HR-/HER2 (triple-negative).

Emerging therapies: Phase II: 24 drugs; Phase III: 15 drugs. Coverage of 8 select preclinical and Phase I products.

Market forecast features: Using a proprietary patient-flow model incorporating mortality, we forecast population sizes and drug sales for all patient segments through 2018.

Alternative market scenarios:  (1) bevacizumab is approved in the adjuvant setting, (2) neratinib fails to launch in the adjuvant setting, and (3) pertuzumab fails to launch for first-line metastatic CaB.

Search Reports

Mentioned in this report:

  • - Abbott
  • - Abraxis BioScience
  • - Agendia
  • - AlphaVax
  • - Amgen
  • - Antigen Express
  • - Apthera
  • - Ariad
  • - AstraZeneca
  • - Aveo Pharmaceuticals
  • - Bavarian Nordic
  • - Baxter
  • - Bayer
  • - BiPar Sciences
  • - Bristol-Myers Squibb
  • - Celera
  • - Celldex Therapeutics
  • - Centocor Ortho Biotech
  • - Cephalon Pharma
  • - Chugai
  • - CSP
  • - Daiichi Sankyo
  • - Dako
  • - Dendreon
  • - Eisai
  • - Eli Lilly
  • - Essex Pharma
  • - Genentech
  • - Generex Biotechnology
  • - Genomic Health
  • - GlaxoSmithKline
  • - ImClone Systems
  • - Immunotope
  • - Immunovative Therapies
  • - Ipsogen
  • - Janssen Pharmaceutica
  • - Johnson & Johnson
  • - Kissei Yakuhin Kog
  • - Kwang Dong Pharmaceuticals
  • - Kyowa Hakko Kirin
  • - Mannkind
  • - Medicopharm
  • - Merck
  • - Merck KGaA
  • - Merck Serono
  • - Nippon Kayaku
  • - Novartis
  • - Oncothyreon
  • - Onyx
  • - OSI Pharmaceuticals
  • - Pfizer
  • - Pierre Fabre
  • - Quantum Immunologics
  • - Quest Laboratories
  • - Regeneron Pharmaceutical
  • - Roche
  • - Sanofi-Aventis
  • - Shionogi
  • - Taiho Pharmaceutical
  • - Takeda
  • - Therion Biologics
  • - Valeant Pharmaceuticals
  • - Zeltia’s PharmaMar
  • - Zeneus Pharma